Frédéric Boisserie

Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber et al. · New England Journal of Medicine · 2006 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 695 citations

Medicine, Oncology, Pharmacology +16

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Masatoshi Kudo, Tim Meyer et al. · JAMA Oncology · 2023 · 249 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Richard S. Finn, Masatoshi Kudo et al. · Future Oncology · 2019 · 153 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Ghassan K. Abou‐Alfa, Óscar Puig, Bruno Daniele et al. · Journal of Hepatology · 2016 · 127 citations

Medicine, Oncology, Pharmacology +8